[Combination of antimycotic preparations and natural proteinase inhibitors in otomycosis].
In vitro experiments, Terrilytinum* increases the antimycotic activity of Clotrimazolum* and Nitrofungin*, and cancels out the inhibitory effect of Contrycal*. The combined application of Clotrimazolum and Nitrofungin with Terrilytinum and Contrycal as treatment of otomycosis of the middle ear has an outstanding clinical and anti-mycotic efficacy. The results of the investigation show that the proposed method of treatment is marked by an excellent therapeutic efficacy in the case of otomycosis.
Soushko
Y A
YA
Institut de recherches scientifiques d'otolaryngologie de Kiev, Ukraine.
Borissenko
O N
ON
Volosevitch
L I
LI
D000293:Adolescent; D000328:Adult; D000368:Aged; D000681:Amylases / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use*; D003022:Clotrimazole / Q000627:therapeutic use; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D004427:Ear Diseases / Q000188:drug therapy* / Q000382:microbiology; D004432:Ear, Middle; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy*; D009596:Nitrophenols / Q000627:therapeutic use; D010447:Peptide Hydrolases / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000627:therapeutic use*
D000935:Antifungal Agents; D004338:Drug Combinations; D009596:Nitrophenols; D011480:Protease Inhibitors; C009402:amylase, phosphates, proteases drug combinations; C002722:nitrofungin; D000681:Amylases; D010447:Peptide Hydrolases; D003022:Clotrimazole